Rapport says drug it licensed from J&J clears Phase 2 bipolar mania study

Rapport Therapeutics said Tuesday its investigational oral drug that dials down the effect of AMPA receptors has cleared a mid-stage trial in bipolar mania, paving the way for registrational studies slated to start next year. ...